Settings and participants
cancer, prostate cancer, Cancer
CANCER, DISEASE, RECRUITMENT, METASTATIC DISEASE, PROSTATE CANCER, CANCER
PACCT was conducted at two National Cancer Institute‐designated comprehensive cancer centers: Wayne State University/Karmanos Cancer Institute (WSU/KCI) in Detroit, Michigan, and Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center (SKCCC) in Baltimore, Maryland. Physicians (medical oncologists, urologists, and radiation oncologists) were eligible to participate if they treated patients with prostate cancer and could recruit patients to available trials. Adult men were eligible if they had a confirmed diagnosis of prostate cancer (locally‐advanced to metastatic); self‐identified as Black, African American, or White and non‐Hispanic; had an ongoing but relatively brief (<1 year) relationship with a participating physician and expected to see the physician at least once in the following year; could read and write English; and could potentially qualify for a therapeutic clinical trial within 2 years of consent (e.g., good performance status, no significant comorbidities). Although patients were technically eligible to participate if they had a confirmed diagnosis of prostate cancer, recruitment of patients with intermediate‐ to high‐risk prostate cancer was prioritized because they were more likely to become eligible for a therapeutic clinical trial than patients with early‐stage, low‐risk disease. Any open prostate cancer trial was appropriate, spanning from peri‐operative, radiation‐based, or drug therapy for recurrent or metastatic disease. The study was approved by the institutional review boards at each site and registered at 